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Detection and time-tracking activation of a
photosensitiser on live single colorectal cancer
cells using Raman spectroscopy†
Julia Gala de Pablo, a,b David R. Chisholm,c,d Carrie A. Ambler,c,e
Sally A. Peyman,a,f Andrew Whiting c,d and Stephen D. Evans*a,f
Raman spectroscopy has been used to observe uptake, metabolism and response of single-cells to drugs.
Photodynamic therapy is based on the use of light, a photosensitiser and oxygen to destroy tumour
tissue. Here, we used single-cell Raman spectroscopy to study the uptake and intracellular degradation of
a novel photosensitiser with a diphenylacetylene structure, DC473, in live single-cells from colorectal
adenocarcinoma cell lines SW480, HT29 and SW620. DC473 was seen to predominantly accumulate in
lipid droplets, showing higher accumulation in HT29 and SW620 cells than in SW480 cells, with a broader
DC473 peak shifted to higher wavenumbers. DC473 activation and effects were tracked on live single-
cells for 5 minutes. Upon exposure to UV light, the DC473 signal intensity dropped, with remaining
DC473 shifting towards higher wavenumbers and widening, with a lifetime of approximately 50 seconds.
Morphologically, SW480 and SW620 cells showed changes upon photodynamic therapy, whereas HT29
cells showed no changes. Morphological changes correlated with higher remaining DC473 signal after UV
exposure. Our research suggests that DC473 forms aggregates within the cells that disaggregate following
activation, showing the potential of Raman spectroscopy for the study of time-dependent single-cell
pharmacodynamics.
Introduction
Drug efficacy or resistance in vitro is often tracked using
single-protein assays. However, this approach may miss the
bigger picture and lead to responses that are not consistent
with in vivo results.1 Raman spectroscopy provides the mole-
cular signature of a sample using the inelastic scattering of
monochromatic light, for the detection of chemical functional
groups.2,3 It is a label-free, non-destructive technique, with
spatial resolution in the micrometre scale, allowing for single-
cell measurements on live cells.4–8 The target compound can
be detected within a cell in a semi-quantitative manner and
related to the cell response.9–11 Raman has been extensively
applied on pharmacological characterization.12
The spontaneous Raman signal is weak, making the tech-
nique inherently slow.4 Additionally, drug peaks often appear
in the cell fingerprint region, merging with bands from com-
ponents such as proteins, lipids and nucleic acids.13 For track-
ing a drug within a cell, alternative approaches can be used,
such as Resonance Raman scattering (RRS), the use of isotopo-
logues such as deuterium labelling14,15 or biorthogonal
Raman tagging such as through alkyne incorporation.13,16–18
RRS has been employed to study cytochrome C at 532 nm,19,20
where a drop in signal intensity, due to oxidation, has been
observed at early stages of apoptosis.19 Biorthogonal Raman
tagging uses molecules that exhibit vibrational bands in the
Raman silent region of cells (1800–2800 cm−1) such as
alkynes, enabling more accurate detection of compounds in
single cells.16–18,21–26 Alternatively, non-linear RS, such as
Coherent anti-Stokes RS (CARS)27 or Stimulated RS (SRS)28 can
be used though they require a more complicated setup with
multiple laser beams making their translation to medical and
biological applications challenging.29
RS has been used to observe both uptake, metabolism and
response of single cells to drug treatment,12 and is often
carried out post fixation of the cells, thereby marking an end-
†Electronic supplementary information (ESI) available. See DOI: 10.1039/
d0an01023e
aMolecular and Nanoscale Physics Group, School of Physics and Astronomy,
University of Leeds, Leeds, UK. E-mail: s.d.evans@leeds.ac.uk
bGoda Lab, School of Science, University of Tokyo, Tokyo, Japan
cLightOx Limited, Wynyard Park House, Wynyard Avenue, Wynyard, Billingham,
TS22 5TB, UK
dDepartment of Chemistry, Durham University, South Road, Durham, DH1 3LE, UK
eDepartment of Biosciences, Durham University, Durham, DH1 3LE, UK
fWelcome Trust Brenner Building, St James’s University Hospital, Faculty of Medicine
and Health, University of Leeds, Leeds, UK
5878 | Analyst, 2020, 145, 5878–5888 This journal is © The Royal Society of Chemistry 2020
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
7 
Ju
ly
 2
02
0.
 D
ow
nl
oa
de
d 
on
 9
/9
/2
02
0 
10
:3
8:
47
 A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
View Journal  | View Issue
point to the experiment. For example, Raman microspectro-
scopic studies were done on the response of cancer cells to
tyrosine kinase inhibitors containing –CuC– or –CuN moi-
eties in lung cancer,1 colorectal cancer30–32 and leukaemia,33
and for detecting drug metabolism within the cell.34,35
Yamakoshi et al. used RS to image the different chemical
forms of a mitochondrial uncoupler with a nitrile Raman tag
on live HeLa cells.18 Spectroscopic studies have also been used
to detect cisplatin binding to DNA in the nucleus,36 cell mem-
brane and cytoplasm37 of lung adenocarcinoma cells.
Doxorubicin accumulation and the cell’s response at different
incubation times was measured on fixed cells using RS.38,39
Internalization of biodegradable biocarrier systems in single
cells has been extensively studied with Raman
microspectroscopy,12,40 with multiple studies on poly(lactide-
co-glycolide) beads.41–45 Microspectroscopy studies give
insights into the responses to the drugs of interest, however,
mapping is time consuming and low throughput, usually in
the tens of cells. In addition, using fixed cells precludes the
ability to perform time-dependent studies on the same single-
cell.
Colorectal cancer (CRC) is the third most common cancer
worldwide and second in mortality, with over 1.8 million new
cases diagnosed in 2018, and more than 850 000 deaths.46
Approximately half of the patients develop metastasis to the
liver47 and resistance to standard chemotherapy.48 Novel thera-
pies for the treatment of CRC are, therefore, needed.
Photodynamic Therapy (PDT) is based on the use of light, a
photosensitizer (PS) and oxygen to destroy tumour tissue
through oxidative damage, vascular shutdown and activation
of immune response against cancer cells.49 DC473 is a low
molecular weight photosensitiser that can be activated by exci-
tation with UV-A, violet or corresponding near-infrared two-
photon wavelengths. DC473 exhibits strong solvatochromic
fluorescence and possesses two alkyne groups.25,50,51 Previous
in vitro studies have reported epithelial cell death, after UV-A
irradiation following incubation with DC473, due to the pro-
duction of reactive oxygen species.51
One of the first reports of Raman detection of photosensiti-
sers within cells was the publication by Freeman et al. in 1997,
detecting zinc phthalocyanines in a fixed human endothelial
hybridoma cell line.52 Abramczyk et al. used Raman micro-
spectroscopy and observed preferential accumulation of alu-
minium phthalocyanine cancerous breast tissue compared to
non-cancerous tissue.53,54 Brozek-Pluska et al. used RS to
provide a map of lipids and proteins and fluorescence to
detect hematoporphyrin and phthalocyanine in healthy and
cancerous breast tissue, showing higher accumulation in the
latter.55,56 In vivo, Bhattacharjee et al. performed RS measure-
ments in breast cancer model rats showing PS accumulation
and PDT effects of chlorin photodithazine.57 An alternative
approach is to use Surface-Enhanced RS (SERS) to increase the
limit of detection of the PS, often done by including metal
nanoparticles in theranostic constructs with the PS.58–64 Fales
et al., used targeted gold nanostar constructs loaded with
PPIX, showing detection and targeting in single cells,65,66 and
Farhadi et al. coupled palladium porphyrin with plasmonic
nanoparticles to allow SERS detection of the PS, using the
same wavelength to excite Raman scattering and to stimulate
PDT.67 To our knowledge, there have been no reports in the
detection of PS accumulation in live single cells using RS, or
in the single-cell pharmacodynamics of the PS upon
activation.
In this manuscript, we study both the accumulation and
the photoactivation of a novel photosensitiser, DC473, in live
single-cells from cell lines representing different stages of col-
orectal cancer. For our model we used an adenocarcinoma
model system comprised by the cell lines SW480, HT29 and
SW620, representing Duke’s stage B primary, Duke’s stage C
primary and Duke’s stage C secondary cell lines, respectively.20
Methods
Cell preparation
Cells were cultured and measured as in our previous work.20
The SW480, HT29 and SW620 cell lines were cultured in
Dulbecco’s Modified Eagle Medium (DMEM/F-12, Gibco) sup-
plemented with 10% fetal bovine serum (Sigma), 2 mM
Glutamax (Thermo Fisher Scientific) and penicillin 100 units
per mL streptomycin 100 µg mL−1 (Sigma). All experiments
were done with passage numbers below 50.
DC473 incubation
Cells were seeded 2 days in advance of the experiment in 6
well plates at a concentration of 3.5 × 105 cells per well. Before
Raman measurements, media was changed and 4 µM of
DC473 in a 0.4% DMSO/media solution was added to the cells
and incubated for 4 h, whereas the control cells received an
equivalent concentation of DMSO (0.4%). Prior to the experi-
ment, cells were washed with Dulbecco’s phosphate-buffered
saline (DPBS) and gently retrieved from 6-well plates by incu-
bating with TrypLe (Thermo Fisher Scientific) for 5 min, fol-
lowed by centrifugation and two washes in DPSB (100 gs
1 min) and re-suspension in cell dissociation buffer (Thermo
Fisher). When pipetted into the setup, cells sedimented onto
the coverslip and showed no visible Brownian motion, remain-
ing in a spherical shape.
Raman spectroscopy
Quartz slides (UQG Optics, 75 × 25 × 1 mm) and coverslips
(25.4 × 25.4 × 0.15–0.25 mm Alfa Aesar) were sonicated with
acetone (VWR Chemicals), 2–5% Decon 90 (VWR Chemicals)
and rinsed with MilliQ. All organics were removed by incu-
bation for 20 minutes in Piranha solution (H2O2 30% (Thermo
Fisher) and H2SO4 > 95% (Thermo Fisher) in a 3 : 7 pro-
portion). Spacers were prepared using a 50 µm polyethylene
terephthalate film (Goodfellow, UK). A nitrocellulose-based
solution was used to bond the coverslip to the slide. The cell
solution was pipetted into this chamber immediately before
measuring. All experiments were done at room temperature
and samples were measured for 1 h.
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The Raman system used was an inVia Raman confocal
inverted microscope (Renishaw) integrated with a Leica DMi8/
SP8 laser scanning confocal microscope system, with a DPSS
Diode 532 nm laser (laser power of 22 mW on the sample) and
a 785 nm laser (laser power of 45 mW at the sample), with
gratings of 1800 l mm−1 and 1200 l mm−1 respectively. Light
was collected using either a Newton EMCCD Sensor (DU970P,
Andor, 1600 × 200 px) for the visible excitation laser or a near-
infrared enhanced CCD array detector (1024 × 256 pixels,
Renishaw). Before each experiment a spectrum of a silicon
sample was collected using the respective objective, grating
and detectors used and the microscope was calibrated to the
peak position (520.5 cm−1).
The cell spectra were obtained using a 100× oil objective
(HC PL APO CS2 FWD 0.13 mm NA 1.4) and a slit size of
either 20 µm (for DC473 accumulation experiments and
DC473 off cell activation experiment) or 65 µm (for DC473
PDT experiments). This objective gave a 10.8 µm and 25.7 µm
Full-Width Half Maximum axial confocality when tracking
the changes of Raman intensity of the 520.5 cm−1 with the
distance to a silicon sample for each of the slit openings. The
laser spot was defocused by 20% using a beam expander, gen-
erating a laser spot of approximately 18 µm diameter, and
obtaining the average signal of the cell. Cell spectra for
DC473 accumulation were obtained using a step configur-
ation with 1 s exposure time and 5 accumulations in two
different windows (300–1800 cm−1 and 1800–3200 cm−1)
which gave a total exposure time of 10 s per cell. For the
DC473 PDT experiments, the 300–1800 cm−1 region was prior-
itized to increase the spectral quality and time resolution.
The data from multiple experiments were combined for this
paper without omitting any outliers, with 135 cells incubated
with DC473 and 134–135 cells as control for each cell line.
Five background spectra from cell-free regions of the sample
measured at the same Z-position as the cells were obtained
for each experiment.
Photodynamic activation of DC473
DC473 off-cell activation was done using a 100 µM DC473 solu-
tion in DMSO, using a 100× oil immersion objective and
340–380 nm UV light with a light intensity of 131 mW cm−2
and a total dose of 5.2 J cm−2. Acquisition was obtained using
the 785 nm excitation before and immediately after activation
(1.13 mJ). For tracking the activation of DC473 on live single
cells, before cell treatment, a Raman spectrum was acquired
setting the system to acquire spectra every 20 s. Then, the PS
was activated using 3 s of UV light, for a total dose of 711 mJ
cm−2. The following acquired spectra tracked the changes in
the cell following the PS activation. Two controls were made,
with cells incubated with DMSO exposed to the Raman acqui-
sition light and cells incubated with DMSO exposed to both
the Raman acquisition light and the UV light, to understand
the phototoxicity due to these light sources in the absence of
the PS. Typically, 10–11 cells were measured per group, acquir-
ing 15 spectra per cell, with a total of around 30–35 cells per
cell line.
Pre-processing of the spectra
The spectra obtained were cosmic ray filtered (WiRE® software)
and exported as text files for further analysis using Matlab’s
Statistics and Machine Learning Toolbox (MathWorks). The
Matlab functions used are indicated by italics. The silicon peak
of a calibration sample was used to calibrate the wavenumber
axis of each spectrum and the spectra were translated vertically,
such that the minimum intensity was zero. For each cell spec-
trum, the average background spectrum of the sample was mul-
tiplied by an adjustment factor before being subtracted from
the cell spectrum. The spectra were truncated to only consider
the regions between 730 cm−1 and 3100 cm−1. The spectra were
baseline corrected using the algorithm developed by Koch et al.
(2016).68 The regions of the spectra between 1750 cm−1 and
2800 cm−1 were not considered for subsequent analysis. In
order to normalize to the protein content, for comparison with
biochemical literature data, each spectrum was normalized
such that the Amide I peak was unity. For the PDT experiments,
where only the fingerprint region was acquired, similar pre-
processing was followed.
Statistical analysis and classification
Statistical errors. Unless stated otherwise, all values are
expressed ±the standard error (SE) calculated as σ/√N, where
σ is the standard deviation and N the sample size. PCA. The
edited data was standardized using Standard Normal Variate.
PCA was used to identify the main sources of variability in the
datasets. The function used was pca. Significance. Significance
was calculated by comparing the single cell observations using
unequal variances t-tests. GLS fitting. GLS fitting was done
based on the description from Jain et al., using Matlab.69 For
the 2195 cm−1 band, the peak was allowed a variation in the
position of ±10 cm−1 and a width of 20 ± 10 cm−1. For the
1597 cm−1 band, the fitting was more challenging due to
overlap from the adjacent Amide I and cytochrome C bands.
Three bands were fitted for the Amide I; namely: α-helix
(1648 cm−1), β-sheet (1667 cm−1) and random coils (1680 cm−1),
all of them with a width of 40 ± 20 cm−1. Additionally, the
1585 cm−1 cytochrome C peak was also fitted (width 40 cm−1).
All peaks were allowed a variation in the peak position of
±5 cm−1 except the DC473 fitted peak at 1597 cm−1, that was
allowed no variation in position to avoid fitting artefacts in
noisy spectra. For the PDT data, the spectra were first filtered by
fitting the amplitude to remove spectra where the band was not
present. This was done so that the amplitude minus the error
was higher than 0.12 for the 1597 cm−1 band and 0.05 for the
2195 cm−1 band. Given the better quality of the spectra from
the PDT dataset, the DC473 phenyl peak in this dataset was
allowed a shift in the fitting position of ±5 cm−1.
Results
Detection of DC473 on live single cells
Fig. 1B shows fluorescent staining of the three cell lines used
in this study: SW480, HT29 and SW620. These cell lines
Paper Analyst
5880 | Analyst, 2020, 145, 5878–5888 This journal is © The Royal Society of Chemistry 2020
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
7 
Ju
ly
 2
02
0.
 D
ow
nl
oa
de
d 
on
 9
/9
/2
02
0 
10
:3
8:
47
 A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
belong to progressive stages of colorectal adenocarcinoma
(Duke’s stage B, C and C metastasis respectively). Nile red
emission is shown in green (triglycerides) and red (phospho-
lipids).70 The three cell lines show distinct morphology and
the presence of lipid droplets (green), HT29 showed a particu-
larly high quantity of lipid droplets around the nucleus,
whereas SW620 showed lipid droplets located near the Poles.
SW480 cells showed lipid droplets both around the nucleus
and near the Poles. As DC473 is a hydrophobic compound,
we expected cells with higher amounts of lipid droplets to
have increased uptake of DC473. In a previous study, we
showed that DC473 in SW480 cells accumulated in lipid dro-
plets and in the cytosol, presumably on the mitochondrial
membrane.25
Using a beam expanded laser spot allowed the relatively fast
acquisition of high-quality averaged spectra per cell. Fig. 1A
shows the chemical structure of DC473.25 Fig. 1C shows the
average spectra for each of the cell lines and comparing the
cells following incubation with DC473, or with DMSO control.
All spectra are normalized to the Amide I band. The five stron-
gest peaks from the spectrum of the pure DC473 (see Fig. S1
and Table S1 from the ESI†) are identified as: 1141 cm−1
(DC473 phenyl), 1597 cm−1 (DC473 phenyl), 1634 cm−1
(DC473 ester) and 2197 cm−1 (DC473 internal alkyne). The
terminal alkyne band that would be expected at lower wave-
numbers was not observed71 which is in agreement with
general observations that terminal alkynes often show weaker
bands than internal and especially conjugated alkynes.23 The
average spectra show uptake of the drug for all cell lines, with
higher DC473/protein content for HT29 and SW620 cells.
DC473 bands were present in all cell lines, where the
1634 cm−1 peak showed as a shoulder on the Amide I band.
DMSO was non-detectable in the samples, based on the
absence of the C–S νS band at 674 cm
−1.
Fig. 1D shows the difference spectra indicating the presence
of not only the main DC473 bands, but also a reduction in the
CH contribution of both the 1445 cm−1 and the stretching
band at 2940 cm−1 following incubation with DC473. This
suggests that DC473 could interfere with lipid metabolism
and/or regulation. A weak band at 1181 cm−1 was also present
in the difference spectra as is associated with the DC473
phenyl peak. We note that incubation with DC473 also corre-
lated with an increase in the 746 cm−1 cytochrome C band,
suggesting that DC473 localised in mitochondria and that it
may interfere with organelle function even before PS
activation.
DC473 band fitting on single cell spectra
To compare the DC473 accumulation in the different cell
lines, we used Gaussian Lorentzian sum (GLS) single cell peak
fitting of the DC473 spectral peaks at 2195 cm−1 and at
1597 cm−1, as detailed in the Methods section. Example fits
are shown in Fig. 2B for the 1594 cm−1 band and Fig. 2D for
the 2194 cm−1 band. The results from the fitted amplitude are
shown in Fig. 2A and C, where the significance between cell
types is also indicated (based on t-test with unequal variances).
All cell lines displayed uptake of DC473, but when comparing
the different cell lines (normalizing to the Amide I band),
SW620 and HT29 exhibited similar levels of uptake and signifi-
cantly higher accumulation of DC473 than SW480 cells, likely
due to the higher presence of lipid droplets (see Fig. 1B).
For the 2195 cm−1 peak, the position and width of the peak
were allowed to vary on a cell by cell basis. Peaks with ampli-
tude lower than 0.15 (normalized to the Amide I band) were
excluded. The mean peak amplitude, width and position
obtained are shown in Table 1. Cell lines with higher accumu-
lation of DC473 showed broader peaks and a shift towards
higher wavenumber. We believe this is related with the local
Fig. 1 A. Chemical structure of DC473. B. Confocal fluorescence images of cells for each cell line, where blue is DNA, and green and red are two
emission channels for Nile Red: triglycerides (green) and phospholipids (red). C. Average spectra of live single cells of the different cell lines, where +
indicates cells following incubation with 4 µM of DC473 and C indicates cells with an equivalent volume of DMSO. The area around the curve
corresponds to one standard deviation and the main DC473 bands have been indicated. The number of cells in each group is N ≥ 134. D. Difference
spectra of the average between DC473 induced cells and control cells for each of the cell lines. All spectra are normalized to the Amide I peak and
have been offset for clarity.
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environment where the compound accumulates within the
cell, with cell lines with more lipid droplets accumulating
more compound in a more hydrophobic environment, with a
small shift towards higher wavenumbers.
The CH stretching band was also analysed at the single cell
level, integrating between 2800 and 3080 cm−1 (see Fig. S2
from the ESI†). Data showed a very significant drop in CH-
stretching bands intensity for all cell lines (p < 10−4) following
incubation with DC473.
Principal component analysis
To further understand the data, PCA was carried out, in which
the smoothing of the spectrum was avoided to increase the
sensitivity of any band position shifting. Fig. S4A (ESI†) shows
the first 4 PCA loadings explaining 21.5% of the total varia-
bility, where the main DC473 (black) and cell (red) peaks have
been labelled. Fig. S4B (ESI†) shows the scores for those first 4
PCs. PCA results confirmed the increase in cytochrome C band
intensity and the overall reduction in the CH stretching inten-
sity following incubation with DC473. This is in line with our
previous results showing accumulation in lipid droplets,25
indicating that the compound could be partially disrupting
lipid accumulation. The positive correlation of cytochrome C
with DC473 suggests that the compound could be interacting
with mitochondria.
DC473 activation off cell
Following our understanding of the accumulation of the com-
pound in these cell lines, further experiments were made to
understand the UV activation mechanisms of DC473. Deep
UV light was effective in bleaching the fluorescence and led
to the loss of the Raman signal of the compound. A 100 µM
solution of DC473 in DMSO was measured before and after
exposure to UV light (340–380 nm, 5.2 J cm−2). The spectra
acquired using the 785 nm excitation line are shown in
Fig. S3 in the ESI,† normalized to the maximum DMSO band.
The exposure to UV light caused a significant drop in the
main Raman bands associated with the alkyne and phenyl
modes, without the appearance of other secondary bands,
indicating that the diphenylacetylene structure of DC473 is
degraded due to UV light exposure, and the resultant degra-
dation products are too weak to detect or exhibit Raman
bands of comparatively weak intensity. It should be noted
that even after prolonged UV exposure, not all the DC473
signal disappeared.
DC473 PDT on live single cells
To study the effects of the DC473 PS in single cells, the cells
were incubated with the compound, then detached from the
well plate and resuspended in buffer before analysis. A Raman
spectrum in the fingerprint region was acquired before UV
treatment. Post UV exposure Raman spectra were acquired
every 20 s, for approximately 5 minutes. Two controls without
the PS were prepared to separate any potential phototoxicity
due to the excitation laser or the UV light used to irradiate the
compound. Specifically, cells were either exposed to the same
UV dose and the Raman laser or just to the Raman laser exci-
tation. We have already shown that DC473 does not degrade
under the 532 nm laser doses used in this experiment, and
thus no control with DC473 and no UV light was undertaken.
Measurements were typically made on around 10–11 cells per
group, with a total of around 30–35 cells per cell line and in
each case 15 spectra per cell.
An example of the data obtained in such an experiment is
shown in Fig. 3A. The DC473 bands at 1597 and at 2195 cm−1
showed a strong contribution in the initial spectrum (t = 0)
which decreased rapidly after PS activation. However, not all
the DC473 signal disappeared; a small amount of the com-
pound remained according to the cell spectra. This data agrees
with the off-cell data, suggesting that DC473 undergoes a sig-
nificant structural change following UV activation and conse-
quently, loses its characteristic Raman signal.
Fig. 2 Comparison of the characteristic DC473 signals in different col-
orectal single cells following incubation with either DC473, or DMSO as
a control. A. Bee swarm and box plots of the amplitudes for the
1594 cm−1 peak fitting. B. Peak fitting for a SW620 cell. C. Bee swarm
and box plots of the amplitudes for the 2194 cm−1 peak. D. Peak fitting
for the alkyne band associated with the DC473 in the same SW60 cell in (B).
Table 1 Summary of fitting parameters for the alkyne peak at
2197 cm−1 for each of the cell lines. The parameters correspond to the
GLS curves ±SE. The number of cells that had an amplitude >0.15 (nor-
malized to Amide I) is shown (N), and were used to calculate the remain-
ing parameters
N
Amplitude
(normalized) Position (cm−1) Width (cm−1)
SW480 121 0.28 ± 0.01 2193.9 ± 0.2 18.8 ± 0.2
HT29 129 0.34 ± 0.02 2195.2 ± 0.2 19.7 ± 0.4
SW620 133 0.33 ± 0.01 2194.8 ± 0.2 21.0 ± 0.5
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Interestingly, changes in the morphology of the treated
cells following the Raman acquisition were detectable for
some cells from the SW480 and SW620 cell lines, as can be
seen in Fig. 3B. Cells would undergo blebbing by the end of
the acquisition (indicated with white arrows), a sign of cell
death and an expected response of PDT. For the controls, only
3% of the cells showed morphology changes, with 2/30 cells
for the UV control and 0/30 cells for the Raman laser control.
From the DC473-treated cells 64% of SW480 cells, 0% of HT29
cells and 60% of SW620 cells showed morphological changes
following PDT. Surprisingly, although the HT29 and SW620
cells displayed very similar DC473 accumulation they had very
different responses to UV activation. However, it must be
noted that the absence of morphological changes at the time
of measurement does not preclude the cells could undergo
apoptosis on longer time scales.
To illustrate the differences in cell responses, the average
initial and final spectra for each cell are shown in Fig. 4
(Control, Control + UV and DC473 + UV). These spectra were
overlaid for each cell line. For the DC473 + UV samples, the
main DC473 bands at 1597 and 2195 cm−1 showed a signifi-
cant reduction in intensity following PDT, but not always down
to undetectable levels (see bands at 1143, 1597, shoulder at
1632 and band at 2195 cm−1). In particular, the SW480 and
SW620 cells often showed detectable levels of DC473 following
UV activation, whilst the HT29 cells showed a drastic reduction
of the compound’s Raman signal. These results confirmed
that the compound was undergoing a chemical modification
within the cells. The differences in photodegradation of the
compound in different cell lines suggest that the compound
may be showing different aggregation states within the cell.
Indeed, it has been shown that diphenyacetylene derivatives
can form liquid crystalline states in solution and that the
highly organised structures formed showed a similar blue
shifted absorption band.72 As the compound accumulates
both in lipid droplets and in the cytosol, the coexistence of
Fig. 3 A. Example of a time-dependent single-cell (SW480) response to the DC473 PDT activation with UV light, where the first spectrum was
taken before activation of the photosensitiser, and the remaining spectra were collected post activation. The data was pre-processed as described in
Methods. B. Bright field images following incubation with DC473 before and after Raman acquisition following PDT treatment with UV light (approx.
5 minutes). Membrane blebbing was observed, as indicated with white arrows.
Fig. 4 Average of the data before (black) and after (red) each PDT
experiment for each of the samples and cell lines, where CRT = Control,
CRT + UV = Control exposed to equivalent dose of UV light, DC473 +
UV = DC473 sample exposed to UV light. The main bands have been
labelled. The area around the curve represents one standard deviation.
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these two states is expected, with the result that these aggre-
gates would be less susceptible to photoactivation due to their
absorption band being shifted. When comparing different cell
lines, the differences observed in the cell’s morphological
changes post treatment can also be linked to the degradation
of the compound, showing that cell lines with remaining
DC473 signal also showed more blebbing, post-treatment. To
understand the observed morphology changes, it must be
noted that the cells may have different resistances to oxidative
stress. SW480 and SW620 cells show KRAS (G12V) mutation,
and HT29 cells show BRAF (V600E) mutation,73 however, the
relation between these mutations and the redox state is not
well understood.74 Furthermore, previous reports showed that
lipid droplets can have a protective effect against reactive
oxygen species,75 which could explain why HT29 cells showed
higher accumulation but no response to the activation of
DC473, compared to SW480 and SW620 cells, that showed
fewer lipid droplets. Additionally, the location of the com-
pound in each cell line might be different and could have a
strong impact in its toxicity following activation. Regarding the
controls, whilst the signal remained largely unchanged, the
cytochrome C bands were observed to decrease (746 and
1128 cm−1) in all treatments indicating some phototoxicity due
to both the PDT, the Raman acquisition laser and UV light dose.
When calculating the difference between the average
spectra, the main effects of the PDT became evident (Fig. S5,
ESI†). Results showed a drop in all DC473 peaks and in cell
bands at 1443, 1181, 1597, 1632 and 2195 cm−1. All datasets
showed negative peaks corresponding to the cytochrome C pro-
gression (746, 1128, 1310 and 1585), indicating phototoxicity
of the excitation 532 nm laser light and of the UV light, with
also DNA signal loss associated with degradation in some of
the samples observed at 781 cm−1. Additional changes were
observed in the band at 1338 cm−1, which has mixed contri-
butions from proteins and nucleic acids, in the lipid band at
1445 cm−1 and on the side of the Amide I at 1674 cm−1.
PCA analysis of DC473 PDT on live single cells
To explore these changes further, PCA was performed. Fig. 5A
shows the loadings for the first 5 coefficients. Fig. S5 (ESI†)
shows the variation of the average scores for each of the con-
ditions and cell lines with time, where the intensity of all
traces was aligned to 0, for t = 0 to better see the trends with
time. The principal component PC2 was mainly associated
with contributions from DC473, whilst PC3 was associated
with cytochrome C and PC4 with the unassigned bands at
1314, 1338, 1362 and 1390 cm−1 which showed a negative
trend over time, being potential biomarkers of the cell
response to DC473 activation. PCA was unable to identify any
clear Raman marker for the cell blebbing (morphology
changes) observed after PDT, and only showed a strong
reduction on PC3 and 4 on all treated cells, in line with the
amount of DC473 that the cells accumulated. A 2D plot of the
single-cell score traces for PC2 and PC4 is shown in Fig. 5B as
a summary of the PCA findings. The initial point for each cell
was shown with a marker, and the subsequent points were
shown as a line trace. The HT29 control group did not show
overall changes with time, whereas SW480 and SW620 cells
showed a drop in the PC4 score over time suggesting these cells
were more sensitive to the phototoxicity of the 532 nm exci-
tation laser and the UV light. PDT samples showed a dramatic
reduction in both coefficients immediately after the UV dose.
Single-cell band fitting of DC473 bands following PDT
To better characterize the changes that DC473 underwent fol-
lowing UV light activation, both the 1592 and the 2195 cm−1
Fig. 5 A. PCA loadings for the first 5 PCs for the PDT data. The main cell peaks (red) and DC473 peaks (black) have been labelled. B. PCA traces for
PC4 and PC2 for the PDT data, where the first time point is shown as a square, and remaining observations in that cell are shown as a trace.
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bands were fitted to Gaussian Lorentzian Sum (GLS) functions.
Fig. 6 shows the average results for all cells after the amplitude
filtering on both DC473 bands, where the area around the
curves corresponds to one standard deviation, and each data
point was an average of at least 20 fittings. As a lot of cells
showed too low band intensity for fitting, all cell lines were
analysed together. Results showed a sharp drop in the ampli-
tude of both bands caused by the UV irradiation, followed by a
plateau. However, the position and widths of the bands
showed a slower time-dependent trend post-UV exposure. The
four curves were fitted to a sigmoid function over time (y =
a/(a + b·exp(−τ·t ))), where a is the asymptote of the sigmoid
(cm−1), b is the ratio between the asymptotic shift and the
initial value (adimensional) and τ (s−1) is the inverse of the
lifetime. The values for the parameters of the fitted curves are
shown on Table 2 (±SE).
The position of the 2195 cm−1 band shifted towards higher
wavenumbers, peaking at 2199.5 cm−1, for a total shift of
∼4.8 cm−1. The 1597 cm−1 band had a slightly smaller shift to
1601.3 cm−1 (∼3.6 cm−1). In terms of the GLS width, the
alkyne band showed an increase in width of ∼4.9 cm−1 whilst
the sharper phenyl band showed a modest increase in width of
around ∼3.0 cm−1. Both bands showed a similar τ constants of
0.02 s−1. The inverse of τ, or the lifetime of these events, is of
approximately 50 s. It has previously been reported with
phenylacetylene that increased order in a liquid matrix leaded
to narrower bands and shifted maximum intensity to lower
wavenumbers.76 We believe that PDT causes the DC473 aggre-
gates, which are resistant to photodegradation,72 to disaggre-
gate, causing the Raman band to widen and to shift to higher
wavenumbers. Additionally, the biological environment of the
drug has a very important role in this process, by either stabi-
lizing or destabilizing these aggregates, and providing sub-
strates for reaction with the compound.
The two most susceptible cell lines to PDT, based on mor-
phological changes, showed residual DC473 post-PDT, whereas
the HT29 cells showed an absence of any remaining DC473
post-PDT, in most observations. In our previous publication we
observed that DC473 localized in both lipid droplets and in
the cytosol.25 We believe that aggregates could be forming with
a shifted absorption band compared to the free compound,
and thus a lower response to the UV light. Upon PDT, the
aggregates would be disrupted, showing a widening and shift
of the Raman band to higher wavenumbers. The presence of
aggregates anti-correlates with the morphological response of
the cells, however, more cell lines need to be studied to
confirm this result. Additionally, the inherent concentration of
potential substrates for reaction with the activated compound
in each cell line is an important factor to explain their
different response to PDT. Further experiments are needed to
confirm the dual behaviour of the compound and to fully
understand the cell toxicity mechanism. Nevertheless, Raman
on live cells proves to be a powerful tool to track the time-
dynamics to drug responses at the single-cell level.
Conclusions
Our experiments indicate that DC473 can be readily taken up
by different CRC cell lines. Raman spectroscopy results indi-
cated that accumulation mainly occurs in lipid droplets and
the cytosol, and was significantly higher for more advanced
adenocarcinoma HT29 and SW620 cells compared to SW480
cells. This is likely linked to their higher lipid droplet content.
However, when activating the compound with UV light, SW480
and SW620 showed clear morphological changes in response
to the drug, whereas HT29 cells showed no change. The
DC473 Raman signal reduced upon activation, however, some
Fig. 6 Average time dependence of the fitting parameters for the 2195
and 1597 cm−1 band, for all cell lines incubated with DC473 and treated
with UV light after amplitude filtering, where the area behind the curve
corresponds to one standard deviation. The point at which the UV dose
was applied has been represented with a vertical blue dashed line. Red
dashed lines show the sigmoid fittings done to the average data.
Table 2 Time dependence sigmoid fittings of the DC473 average band
GLS fitting parameters: band position and width (cm−1). The corres-
ponding fittings are shown in Fig. 6
Position/cm−1
Band a/cm−1 b τ/s−1
2195 2199.5 ± 0.2 0.0024 ± 0.0003 0.020 ± 0.004
1597 1601.3 ± 0.3 0.0018 ± 0.0004 0.02 ± 0.01
Width/cm−1
a/cm−1 b τ/s−1
2195 23.9 ± 0.4 0.25 ± 0.04 0.021 ± 0.007
1597 13.7 ± 0.4 0.29 ± 0.08 0.02 ± 0.01
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inactivated compound remained for SW480 and SW620 cells,
whilst there was minimal compound left in HT29 cells. It is
known that diphenylacetylenes can form highly organised
aggregates with blue shifted absorption bands,72 which would
make them less susceptible to the PDT UV light. Multivariate
analysis identified coefficients that showed time-dependent
changes in multiple cell peaks over time after DC473 acti-
vation, including cytochrome C bands. The main two DC473
peaks at 1597 and 2195 cm−1 showed a significant drop in
intensity after irradiation and additional shift to higher wave-
numbers and increase in peak width over time at the single
cell level. These changes happened with a lifetime of approxi-
mately 50 s. These effects possibly indicate a change in the
aggregation state of the compound, with disruption of the
aggregates causing the widening and shift of the bands to
higher wavenumbers.76 Our results indicate that the com-
pound could be suitable for CRC PDT, with higher accumu-
lation on lipid droplet rich cancer stages. However, its effects
in lipid metabolism need further understanding and some
cells could be resistant to this treatment, as the data for HT29
seems to indicate. The results showed limited phototoxicity
due to the UV and Raman excitation light sources and that
this may also be different on different cell lines. Finally, the
results also highlight heterogeneity both in the accumulation
and response to PDT both between and within cell lines,
underlining the importance of single cell studies. Further
research needs to be done to understand the biological mecha-
nism behind phototoxicity of the compound in these cell
lines. These findings confirm the feasibility of doing live
single cell drug studies using RS, with sensitivity to cell viabi-
lity and chemical and environmental changes in the drug over
time.
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